BiotechTube
NeuroQure

NeuroQure

Cambridge, United States· Est.
neuroqure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NeuroQure is pioneering a diagnostic paradigm shift in autism spectrum disorder through its proprietary ASD Insight™ test. The test detects a functional calcium signaling biomarker in skin cells, offering the potential for risk assessment from birth, which is significantly earlier than the current standard of care reliant on behavioral observation. This early detection is designed to enable earlier access to interventions, which studies suggest can improve developmental outcomes. The company is commercializing this test directly to patients and healthcare providers, positioning itself at the intersection of diagnostics, personalized medicine, and neurodevelopmental health.

Neurodevelopmental Disorders

Technology Platform

Proprietary diagnostic platform analyzing functional calcium (Ca2+) signaling dynamics in skin fibroblasts to identify a biophysical biomarker associated with autism spectrum disorder (ASD) risk.

Opportunities

The massive unmet need for early, objective ASD detection in a pediatric market affecting ~1 in 36 children creates a significant commercial opportunity.
The functional biomarker platform also holds potential for future applications in patient stratification for clinical trials or discovery of novel therapeutic targets for neurodevelopmental disorders.

Risk Factors

Key risks include the need for extensive independent clinical validation to prove predictive utility, challenges in market adoption due to the invasive nature of a skin biopsy for risk screening, and establishing consistent insurance reimbursement for the test.
The scientific premise, while published, may face competition from other biomarker approaches.

Competitive Landscape

NeuroQure is first-to-market with a functional cellular biomarker test for ASD risk. Competition includes companies offering genetic testing for syndromic forms of ASD (e.g., Lineagen, Centogene), behavioral screening tools (e.g., M-CHAT), and research entities pursuing metabolic, EEG, or other biomarker approaches. NeuroQure's differentiation is its focus on a functional, post-genomic pathway dysfunction applicable to sporadic ASD.

More companies in Diagnostics & Precision Medicine →More companies in United States →